Physician profile
Mark L Cain
NPI 1174558191
$3,199.17
in general payments reported to CMS, 2019-2025
33 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $311 · 2021: $460 · 2022: $824 · 2023: $1,098 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $435.06 | 2023-2025 | Aquabeam Robotic System |
| Astellas Pharma US INC | $282.30 | 2019-2022 | |
| Teleflex LLC | $261.57 | 2023 | Urolift |
| Boston Scientific Corporation | $226.27 | 2019-2023 | Spaceoar System |
| Bayer Healthcare Pharmaceuticals INC. | $203.86 | 2021-2023 | |
| Janssen Biotech, INC. | $193.79 | 2019-2023 | Erleada |
| Myovant Sciences INC. | $193.37 | 2021-2022 | |
| Pfizer INC. | $150.63 | 2019-2023 | |
| Axonics, INC. | $138.29 | 2022-2023 | Axonics |
| Allergan, INC. | $117.44 | 2019-2021 | |
| Abbvie INC. | $110.11 | 2020-2023 | Botox |
| Urovant Sciences INC | $108.80 | 2022 | |
| Urogen Pharma, INC. | $97.20 | 2022 | |
| Cook Medical LLC | $96.36 | 2020 | |
| Sumitomo Pharma America, INC. | $59.82 | 2023 | Orgovyx |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $56.37 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $50.35 | 2022-2023 | Lynparza |
| Rochester Medical Corporation | $42.22 | 2021 | |
| Clarus Therapeutics INC. | $41.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $38.32 | 2022 | |
| Coloplast Corp | $37.43 | 2020-2023 | Titan |
| Dentsply Ih INC. | $35.94 | 2020 | |
| Accord Healthcare, INC. | $31.18 | 2023 | |
| Endo Pharmaceuticals INC. | $30.92 | 2020 | |
| Antares Pharma, INC. | $27.41 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Merck Sharp & Dohme LLC | $26.97 | 2022-2023 | Keytruda, Lynparza |
| Travere Therapeutics, INC. | $21.21 | 2019-2022 | |
| Laborie Medical Technologies Corp. | $17.98 | 2023 | |
| Smith+Nephew, INC. | $15.11 | 2022 | |
| Acerus Pharmaceuticals Corporation | $14.19 | 2021 | |
| Cardinal Health 414 LLC | $13.75 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.25 | 2022 | |
| Ambu INC. | $10.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.